SCHEMBL25300075

SCHEMBL25300075

COC(=O)c1cc(C)nnc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 1/20 0.43
CASP1 P29466 2/20 0.42
ABL1 P00519 1/20 0.42
KMT2A Q03164 1/20 0.41
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
LMNA P02545 1/20 0.39
SERPINH1 P50454 1/20 0.39
NQO2 P16083 1/20 0.38
OPRK1 P41145 2/20 0.38
CA12 O43570 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30501175 1.00 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDCASP1ABL1
SCHEMBL2621657 0.83 ALDH1A1 (0.54) ALDH1A1KDM4ECASP1ABL1GAA
SCHEMBL30567603 0.83 ALDH1A1 (0.54) ALDH1A1KDM4ECASP1ABL1GAA
SCHEMBL30508732 0.82 CASP1 (0.61) ALDH1A1KDM4ECASP1KMT2AMAPT
SCHEMBL26287969 0.82 CASP1 (0.61) ALDH1A1KDM4ECASP1KMT2AMAPT
SCHEMBL17633536 0.81 ABL1 (0.42) ALDH1A1KDM4ECASP1ABL1GAA
SCHEMBL31201869 0.81 OPRK1 (0.47) ALDH1A1KDM4EHPGDCASP1MAPT
SCHEMBL31201866 0.79 KDM4E (0.44) ALDH1A1KDM4EHPGDKMT2AGAA
SCHEMBL1713978 0.79 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDCASP1SMN1; SMN2
SCHEMBL11910412 0.79 SMN1; SMN2 (0.43) ALDH1A1KDM4EHPGDCASP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746965-A1 BENZIMIDAZOLES AS SIK-ACTIVITY MODULATORS F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
EP-4746964-A1 NEW PYRAZOLOPYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
WO-2026046976-A1 PYRAZOLOPYRIDINE PHOSPHATE ESTERS FOR MODULATING SALT-INDUCIBLE KINASE (SIK) F. HOFFMANN-LA ROCHE AG (CH) 2026-03-05 WO disclosed
WO-2025017078-A1 NEW PYRAZOLOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO disclosed
WO-2025017041-A1 BENZIMIDAZOLES AS SIK-ACTIVITY MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO disclosed
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors SIGNALRX PHARMACEUTICALS, INC. (US) 2023-09-19 US disclosed
WO-2023118011-A1 MICROBIOCIDAL AZA-HETEROBIARYL DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors CDK1, CDKN1A, CDKL1 ALDH1A1 3077/4885KDM4E 1229/4885HPGD 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.